Rohan Jalalizadeh, MD
Ophthalmology · Saint Louis, MONPI 1972957538
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,252 of the $7,647 with a category attached, or 81.7%. 15 manufacturers reported payments, led by Alimera Sciences, Inc. at 34.6% of the total. Reporting peaked in 2024 at $3,220 and has fallen 68.1% since, to $1,029 in 2025.
Across 124 payments — averaging $61.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$3K
- Regeneron$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Genentech USA, Inc.$492
- Astellas Pharma US Inc$360
- Bausch & Lomb Americas Inc.$341
- plus $1K from 9 others
What the payments were for
- Consulting fees$1,37518%
- Food & beverage$6,25282%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 17 | $2,649 |
| Regeneron | 1 | $1,375 |
| Regeneron Healthcare Solutions, Inc. | 33 | $1,166 |
| Genentech USA, Inc. | 19 | $492 |
| Astellas Pharma US Inc | 13 | $360 |
| Bausch & Lomb Americas Inc. | 17 | $341 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $325 |
| Dutch Ophthalmic, USA | 3 | $205 |
| Apellis Pharmaceuticals, Inc. | 3 | $163 |
| Biogen | 2 | $155 |
| Ocular Therapeutix, Inc. | 1 | $150 |
| Genentech, Inc. | 1 | $144 |
| ANI Pharmaceuticals, Inc. | 3 | $54 |
| AbbVie | 3 | $46 |
| Eyepoint US, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$2,151
- YUTIQ$1,760
- EYLEA$1,375
- EYLEA HD$242
- SUSVIMO$144
- VABYSMO$144
- EVA, combined machine$120
- TISSUEBLUE$120
- STELLARIS$118
- Bausch + Lomb$118
- OPHTHALMIC INSTRUMENTS$118
- Syfovre$114
How this compares
$7,647 in reported general payments places this provider in the 85th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 270 | $8,740 |
| Brimonidine Tartrate | 55 | $1,818 |
| Ciprofloxacin Hcl | 148 | $1,670 |
| Ketorolac Tromethamine | 51 | $1,478 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 89 | $1,000 |
| Acetazolamide ErAcetazolamide | 16 | $653 |
| Latanoprost | 18 | $194 |
| Timolol Maleate | 20 | $184 |
| Ofloxacin | 12 | $161 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Saint Louis
- Ranjan MalhotraSaint Louis$809K
- Gregg BerdySaint Louis$360K
- Rajendra ApteSaint Louis$112K
- Ian PithaSaint Louis$85K
- Senthil KrishnasamySaint Louis$46K
- Navin TekwaniSaint Louis$34K
- Steven LeeSaint Louis$33K
- John GalanisSaint Louis$20K
- Bruce CohenSaint Louis$11K
- Waseem AnsariSaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.